Skip to content

Ablative, fractional CO2 laser and medical needling to enhance burn scarring in children: A pilot randomised trial

The efficacy of ablative, fractional CO2 laser and medical needling to enhance burn scar remodelling in children: A pilot randomised trial, feasibility and acceptability study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619001317189
Acronym
Not applicable
Enrollment
0
Registered
2019-09-26
Start date
2019-11-25
Completion date
2020-04-17
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to conduct a pilot randomised trial at the Queensland Children’s Hospital with children with burn scars to determine the effectiveness of ablative fractional CO2 laser therapy or medical needling therapy for the treatment of thickened burn scars. Both the interventions of medical needling and ablative fractional CO2 laser are believed to improve scarring by creating microscopic holes in the scar tissue that assist to remodel the scarring. It is hypothesised that either medical needling or ablative fractional CO2 laser is more effective than usual care at improving children's outcomes. This trial will pave the way for a larger multi-centre randomised trial of the three included interventions in children.

Interventions

Intervention arm 1 - Ablative fractional CO2 laser therapy + standard care: Ablative fractional CO2 laser therapy will be delivered by a surgeon to each participant under a general anaesthetic using a Lumenis Ablative Fractional CO2 laser with DEEP FX, SCAAR FX setting; ARTG no. 182239. The dosage applied by the laser intervention will be 120-130mJ, 1% density, square size 10, 250Hz, 1 pass with minimal overlapping. 120MJ will be the dose applied to scarred skin without contractures or tightness

Intervention arm 1 - Ablative fractional CO2 laser therapy + standard care: Ablative fractional CO2 laser therapy will be delivered by a surgeon to each participant under a general anaesthetic using a Lumenis Ablative Fractional CO2 laser with DEEP FX, SCAAR FX setting; ARTG no. 182239. The dosage applied by the laser intervention will be 120-130mJ, 1% density, square size 10, 250Hz, 1 pass with minimal overlapping. 120MJ will be the dose applied to scarred skin without contractures or tightness and 130MJ will be the dose applied to areas with contractures or tightness. The dose applied and areas these doses were applied will be recorded as part of a fidelity checklist. Blood and extradite may also aid in the healing process thus will not be removed during the theatre session. Delivered individually in 3 sessions, each 1-month apart at 2-months post-burn, 4-months post-burn and 6-months post-burn. The site will be covered with a Sorbact dressing immediately post-intervention until removal approximately 24 hours later and following that paraffin cream will be applied as many times a day as needed to prevent dryness of the skin site. The duration of the intervention will vary for each participant and will be determined by the treating surgeon but will usually be for no longer than 1 hour under general anaesthetic. A factsheet will be provided to the caregivers of participants with post-procedural information regarding ongoing treatment, aftercare of the treatment site, potential adverse effects, and staff contact details. Standard care is as per the standard care group with the exception of brief cessation of standard care interventions post-operatively. Silicone and pressure garment therapy will be recommenced after re-epithelialisation post laser intervention. Intervention arm 2 - Medical needling + standard care: Medical needling will be delivered mechanically by a surgeon to each patient under a general anaesthetic using 3mm needles attached to a roller (Environ Roll-CIT 3mm). For sites such as small fingers and curved sites where the roller is difficult to apply, a dermapen will be used for the needling. Blood and extradite may also aid in the healing process thus will not be removed during the theatre session. Delivered individually in 3 sessions, each 2-months apart at 2-months post-burn, 4-months post-burn and 6-months post-burn. The site will be covered with a Sorbact dressing immediately post-intervention until removal approximately 24 hours later and following that paraffin cream will be applied as many times a day as needed to prevent dryness of the skin site. The duration of the intervention will vary for each participant and will be determined by the treating surgeon but will usually be for no longer than 1 hour under general anaesthetic. Standard care is as per the standard care group with the exception of the medical needling intervention which will not be delivered to this group from 6-months to 12-months post-burn (the study endpoint). with the exception of brief cessation of standard care interventions post-operatively. In addition there will be a short period of cessation of standard care interventions post-operatively. Silicone and pressure garment therapy will be recommenced after re-epithelialisation post needling. A factsheet will be provided to the caregivers of participants with post-procedural information regarding ongoing treatment, aftercare of the treatment site, potential adverse effects, and staff contact details. The medical needling or ablative fractional CO2 laser component of intervention arm 1 and intervention arm 2 will be delivered in an operating theatre in a major metropolitan children's hospital. Intervention arm 3 - standard care: Standard care may include pressure garments, silicone products, skin or scar massage, exercises, moisturisers, education regarding sun protection, medical needling (as per intervention arm 2 but from 6-months post-burn). The dose and type of interventions provided is determined by treating health professionals. One or more of these interventions may be provided. The medical needling component of the intervention is delivered in an operating theatre in a major metropolitan children's hospital.

Sponsors

The University of Queensland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years
Healthy volunteers
No

Inclusion criteria

Participants will be aged 16 years or younger at the time of recruitment and have: Hypertrophic burn scarring of any size at up to 2-months post-burn; and be: • Able to attend the study sites for treatment and follow-up; • Hypertrophic scars with functional and/or cosmetic implications determined by patient-report on the Brisbane Burn Scar Impact Profile.

Exclusion criteria

• Hypersensitivity to light/laser treatments as laser therapy would be contraindicated; • Co-morbid skin disorders (i.e., eczema, dermatitis, skin cancer) as these could confound wound healing and scarring post-intervention.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026